Greenwich LifeSciences (GLSI) provided additional updates on its cash burn rate and financing strategy for its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences. The company’s ATM financing vehicle allows the company to sell its common stock directly into the trading market at market price. The amount raised through the ATM for 2025 exceeded the company’s 2025 cash burn rate of approximately $9.5M, leading to a year end cash balance of approximately $6M as of December 31, 2025. Furthermore, the company more than doubled its cash balance as of the close of business on January 23, 2026, to approximately $12.5M, having raised approximately $7M in the first three weeks of January 2026 through the ATM.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI:
- Greenwich LifeSciences’ GP2 breast cancer therapy approved by FDA
- GLSI-100’s Expanded Efficacy and Market Potential Drive Higher Valuation and Reiterated Buy Rating
- Greenwich LifeSciences price target raised to $50 from $39 at H.C. Wainwright
- Greenwich LifeSciences extends lock-up of directors, officers to September 30
- Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters